简介：　　【摘要】 目的 分析阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作（ TIA）的临床效果。方法 96例 TIA患者， 应用随机数字表法分为研究组和对照组， 各 48例。对照组患者单独应用氯吡格雷进行治疗；研究组患者联合氯吡格雷与阿托伐他汀钙片进行治疗。使用生化分析仪对患者的血脂四项 [甘油三酯（ TG）、总胆固醇（ TC）、高密度脂蛋白胆固醇（ HDL-C）和低密度脂蛋白胆固醇（ LDL-C） ]、凝血功能指标 [包括凝血酶原时间（ PT）、活化部分凝血活酶时间（ APTT）和血小板（ PLT） ]进行测定， 对比不良心血管事件发生率。结果 治疗后， 研究组患者的 TG、 TC、 LDL-C等血脂指标明显低于对照组， HDL-C明显高于对照组， 差异具有统计学意义（ P<0.05）。两组患者的凝血时间指标比较差异无统计学意义（ P>0.05）。研究组患者的不良心血管事件发生率为 4.17%， 低于对照组的 18.75%， 差异具有统计学意义（ P<0.05）。研究组患者不良反应发生率为 12.50%， 对照组患者不良反应发生率为 6.25%， 两组比较差异无统计学意义（ P>0.05）。结论 阿托伐他汀联合氯吡格雷治疗 TIA能够调整血脂水平、预防心血管不良事件的发生， 效果对比单独使用氯吡格雷明显更好， 具有较高的应用价值。  　　【关键词】 阿托伐他汀；氯吡格雷；短暂性脑缺血发作；临床疗效  Objective to analyze the clinical effect of Atorvastatin Combined with clopidogrel in the treatment of transient ischemic attack (TIA). Methods 96 patients with TIA were randomly divided into the study group and the control group, 48 cases in each group. The patients in the control group were treated with clopidogrel alone, and the patients in the study group were treated with clopidogrel and Atorvastatin Calcium Tablets. Four blood lipids [TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), and blood coagulation function index [including prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet (PLT)] were performed with biochemical analyzer. The incidence of adverse cardiovascular events was compared. Results after treatment, the blood lipid indexes such as TG, TC and LDL-C in the study group were significantly lower than those in the control group, and the HDL-C was significantly higher than that of the control group. The difference was statistically significant (P<0.05). There was no significant difference in coagulation time between the two groups (P>0.05). The incidence of adverse cardiovascular events in the study group was 4.17%, lower than that in the control group (18.75%), the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group was 12.50%, and the incidence of adverse reactions in the control group was 6.25%. There was no significant difference between the two groups (P>0.05). Conclusion Atorvastatin Combined with clopidogrel in the treatment of TIA can adjust the level of blood lipid and prevent the occurrence of adverse cardiovascular events. The effect is better than clopidogrel alone. It has high application value.